Do analysts rate INDP or CGEM?

Cullinan Therapeutics has a consensus price target of $32.00, suggesting a potential upside of 133.58%. Given Cullinan Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cullinan Therapeutics is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cullinan Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63

Which has stronger valuation & earnings, INDP or CGEM?

Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Indaptus Therapeutics N/A N/A -$20.85M -$15.40 N/A Cullinan Therapeutics N/A N/A -$219.88M -$3.36 N/A

Is INDP or CGEM more profitable?

Cullinan Therapeutics' return on equity of -51.45% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Indaptus Therapeutics N/A -1,030.07% -299.69% Cullinan Therapeutics N/A -51.45% -47.64%

Which has stronger valuation and earnings, OLMA or INDP?

Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Olema Pharmaceuticals N/A N/A -$162.45M -$2.02 N/A Indaptus Therapeutics N/A N/A -$20.85M -$15.40 N/A

Is OLMA or INDP more profitable?

Olema Pharmaceuticals' return on equity of -46.00% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Olema Pharmaceuticals N/A -46.00% -41.22% Indaptus Therapeutics N/A -1,030.07% -299.69%

Do analysts prefer INDP or ALVO?

Alvotech has a consensus target price of $7.60, indicating a potential upside of 82.25%. Given Alvotech's stronger consensus rating and higher probable upside, analysts plainly believe Alvotech is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Alvotech 2 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend SANA or INDP?

Sana Biotechnology presently has a consensus target price of $9.50, suggesting a potential upside of 254.48%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, research analysts clearly believe Sana Biotechnology is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sana Biotechnology 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67 Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, SANA or INDP?

Sana Biotechnology is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sana Biotechnology N/A N/A -$244.17M -$0.93 N/A Indaptus Therapeutics N/A N/A -$20.85M -$15.40 N/A

Is SANA or INDP more profitable?

Sana Biotechnology's return on equity of -108.01% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sana Biotechnology N/A -108.01% -40.68% Indaptus Therapeutics N/A -1,030.07% -299.69%

Do analysts prefer INDP or SPRY?

ARS Pharmaceuticals has a consensus price target of $28.60, indicating a potential upside of 193.03%. Given ARS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ARS Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Indaptus Therapeutics (INDP) Competitors

$3.58 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$3.50 -0.09 (-2.37%)

As of 06/12/2026 07:54 PM Eastern

Compare

INDP vs. CGEM, OLMA, ALVO, SANA, and SPRY

Should you buy Indaptus Therapeutics stock or one of its competitors? MarketBeat compares Indaptus Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Indaptus Therapeutics include Cullinan Therapeutics (CGEM), Olema Pharmaceuticals (OLMA), Alvotech (ALVO), Sana Biotechnology (SANA), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical products" industry.

How does Indaptus Therapeutics compare to Cullinan Therapeutics?

Indaptus Therapeutics (NASDAQ:INDP) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

7.1% of Indaptus Therapeutics shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 23.6% of Indaptus Therapeutics shares are held by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Cullinan Therapeutics had 7 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 9 mentions for Cullinan Therapeutics and 2 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.44 beat Cullinan Therapeutics' score of 0.53 indicating that Indaptus Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Indaptus Therapeutics	Positive
Cullinan Therapeutics	Positive

Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

Cullinan Therapeutics' return on equity of -51.45% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

Cullinan Therapeutics has a consensus price target of $32.00, suggesting a potential upside of 133.58%. Given Cullinan Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cullinan Therapeutics is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Indaptus Therapeutics has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, suggesting that its share price is 101% less volatile than the broader market.

Summary

Cullinan Therapeutics beats Indaptus Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Olema Pharmaceuticals?

Olema Pharmaceuticals (NASDAQ:OLMA) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

In the previous week, Olema Pharmaceuticals had 3 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 5 mentions for Olema Pharmaceuticals and 2 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.44 beat Olema Pharmaceuticals' score of 0.38 indicating that Indaptus Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Olema Pharmaceuticals	Neutral
Indaptus Therapeutics	Positive

Olema Pharmaceuticals currently has a consensus price target of $44.10, indicating a potential upside of 346.81%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Olema Pharmaceuticals is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A

Olema Pharmaceuticals' return on equity of -46.00% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-46.00%	-41.22%
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%

Olema Pharmaceuticals has a beta of 1.98, meaning that its share price is 98% more volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.25, meaning that its share price is 25% more volatile than the broader market.

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 12.6% of Olema Pharmaceuticals shares are owned by insiders. Comparatively, 23.6% of Indaptus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Olema Pharmaceuticals beats Indaptus Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Alvotech?

Indaptus Therapeutics (NASDAQ:INDP) and Alvotech (NASDAQ:ALVO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

Alvotech has higher revenue and earnings than Indaptus Therapeutics. Alvotech is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A
Alvotech	$559.42M	2.25	$27.92M	-$0.25	N/A

Indaptus Therapeutics has a net margin of 0.00% compared to Alvotech's net margin of -14.36%. Alvotech's return on equity of -11.92% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%
Alvotech	-14.36%	-11.92%	-7.59%

Alvotech has a consensus target price of $7.60, indicating a potential upside of 82.25%. Given Alvotech's stronger consensus rating and higher probable upside, analysts plainly believe Alvotech is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

7.1% of Indaptus Therapeutics shares are held by institutional investors. 23.6% of Indaptus Therapeutics shares are held by insiders. Comparatively, 0.5% of Alvotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Indaptus Therapeutics has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market. Comparatively, Alvotech has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market.

In the previous week, Alvotech had 6 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 8 mentions for Alvotech and 2 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.44 beat Alvotech's score of 0.76 indicating that Indaptus Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Indaptus Therapeutics	Positive
Alvotech	Positive

Summary

Alvotech beats Indaptus Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Sana Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

Sana Biotechnology has a beta of 2.14, indicating that its share price is 114% more volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market.

Sana Biotechnology's return on equity of -108.01% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%

Sana Biotechnology is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A

In the previous week, Sana Biotechnology had 2 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 4 mentions for Sana Biotechnology and 2 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.44 beat Sana Biotechnology's score of 0.31 indicating that Indaptus Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Sana Biotechnology	Neutral
Indaptus Therapeutics	Positive

Sana Biotechnology presently has a consensus target price of $9.50, suggesting a potential upside of 254.48%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, research analysts clearly believe Sana Biotechnology is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

88.2% of Sana Biotechnology shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 25.4% of Sana Biotechnology shares are held by insiders. Comparatively, 23.6% of Indaptus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Sana Biotechnology beats Indaptus Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Indaptus Therapeutics compare to ARS Pharmaceuticals?

Indaptus Therapeutics (NASDAQ:INDP) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

7.1% of Indaptus Therapeutics shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 23.6% of Indaptus Therapeutics shares are owned by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, ARS Pharmaceuticals had 4 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 6 mentions for ARS Pharmaceuticals and 2 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.44 beat ARS Pharmaceuticals' score of 0.41 indicating that Indaptus Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Indaptus Therapeutics	Positive
ARS Pharmaceuticals	Neutral

Indaptus Therapeutics has higher earnings, but lower revenue than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A
ARS Pharmaceuticals	$84.28M	11.50	-$171.30M	-$2.01	N/A

Indaptus Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. ARS Pharmaceuticals' return on equity of -153.61% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%

Indaptus Therapeutics has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

ARS Pharmaceuticals has a consensus price target of $28.60, indicating a potential upside of 193.03%. Given ARS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

ARS Pharmaceuticals beats Indaptus Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Indaptus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INDP vs. The Competition

Export

Metric	Indaptus Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$405.41M	$2.99B	$6.52B	$12.05B
Dividend Yield	N/A	1.76%	2.67%	5.66%
P/E Ratio	-0.23	18.84	24.00	24.42
Price / Sales	N/A	326.45	515.84	118.72
Price / Cash	N/A	55.88	27.48	37.92
Price / Book	2.56	3.98	10.60	6.82
Net Income	-$20.85M	$75.79M	$3.57B	$337.56M
7 Day Performance	70.48%	1.57%	0.59%	1.16%
1 Month Performance	125.16%	-0.73%	1.54%	3.16%
1 Year Performance	-60.64%	23.44%	25.41%	30.60%

Indaptus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INDP Indaptus Therapeutics	1.2966 of 5 stars	$3.58 flat	N/A	-60.6%	$405.41M	N/A	N/A	6	Positive News
CGEM Cullinan Therapeutics	3.6403 of 5 stars	$15.21 -0.8%	$30.75 +102.2%	+59.1%	$942.77M	N/A	N/A	30	Analyst Upgrade
OLMA Olema Pharmaceuticals	2.5164 of 5 stars	$10.51 -1.7%	$44.10 +319.6%	+136.7%	$933.74M	N/A	N/A	70	Gap Up
ALVO Alvotech	3.1604 of 5 stars	$3.14 +4.7%	$7.60 +142.0%	-57.2%	$905.42M	$588.90M	N/A	1,460
SANA Sana Biotechnology	2.2142 of 5 stars	$3.12 -3.7%	$9.50 +204.5%	+3.5%	$901.66M	N/A	N/A	380	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INDP) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Indaptus Therapeutics (INDP) Competitors

INDP vs. CGEM, OLMA, ALVO, SANA, and SPRY

How does Indaptus Therapeutics compare to Cullinan Therapeutics?

Summary

How does Indaptus Therapeutics compare to Olema Pharmaceuticals?

Summary

How does Indaptus Therapeutics compare to Alvotech?

Summary

How does Indaptus Therapeutics compare to Sana Biotechnology?

Summary

How does Indaptus Therapeutics compare to ARS Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDP vs. The Competition

Indaptus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Indaptus Therapeutics (INDP) Competitors

INDP vs. CGEM, OLMA, ALVO, SANA, and SPRY

How does Indaptus Therapeutics compare to Cullinan Therapeutics?

Do institutionals & insiders hold more shares of INDP or CGEM?

Does the media prefer INDP or CGEM?

Which has stronger valuation & earnings, INDP or CGEM?

Is INDP or CGEM more profitable?

Do analysts rate INDP or CGEM?

Which has more volatility & risk, INDP or CGEM?

Summary

How does Indaptus Therapeutics compare to Olema Pharmaceuticals?

Does the media refer more to OLMA or INDP?

Do analysts prefer OLMA or INDP?

Which has stronger valuation and earnings, OLMA or INDP?

Is OLMA or INDP more profitable?

Which has more volatility and risk, OLMA or INDP?

Do insiders & institutionals hold more shares of OLMA or INDP?

Summary

How does Indaptus Therapeutics compare to Alvotech?

Which has preferable valuation and earnings, INDP or ALVO?

Is INDP or ALVO more profitable?

Do analysts prefer INDP or ALVO?

Do institutionals and insiders have more ownership in INDP or ALVO?

Which has more volatility & risk, INDP or ALVO?

Does the media favor INDP or ALVO?

Summary

How does Indaptus Therapeutics compare to Sana Biotechnology?

Which has more volatility & risk, SANA or INDP?

Is SANA or INDP more profitable?

Which has better valuation & earnings, SANA or INDP?

Does the media refer more to SANA or INDP?

Do analysts recommend SANA or INDP?

Do insiders & institutionals believe in SANA or INDP?

Summary

How does Indaptus Therapeutics compare to ARS Pharmaceuticals?

Do institutionals and insiders believe in INDP or SPRY?

Does the media prefer INDP or SPRY?

Which has preferable valuation & earnings, INDP or SPRY?

Is INDP or SPRY more profitable?

Which has more risk & volatility, INDP or SPRY?

Do analysts prefer INDP or SPRY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDP vs. The Competition

Indaptus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools